Palomar Holdings walked into its Q1 2026 earnings report carrying a 12% weekly loss. It walked out with a beat and a $200 million buyback. That combination is the central tension this week: the underlying business delivered, while the stock had already been pricing in something worse.
The earnings print, released after the close on May 6, was unambiguously positive. Adjusted EPS came in at $2.31, beating the $2.16 consensus. Revenue of $261.4 million cleared the $250.7 million estimate. On the same day, the company announced a $200 million share repurchase programme running through May 2028 — a significant commitment for a company this size. The question now is how much of that is already captured in any after-hours reaction, and how much the market discounts against a week in which PLMR fell 12%, touching $111.73 at the close.
Positioning heading into the print was notably unbothered by the decline. Short interest, at 2.3% of free float, is modest and was actually lighter on the week — down roughly 3% over seven days despite rising around 11% over the past month. The borrow market reflects the same calm: cost to borrow has eased to 0.35%, down from 0.55% in mid-April and near its lowest level of the recent period. Availability is ample. This is not a stock with meaningful short-side pressure. The ORTEX short score of 32 puts it well below the level where squeeze dynamics become a consideration. Options traders were similarly relaxed — the put/call ratio of 0.27 is slightly below its 20-day average of 0.28, suggesting no unusual demand for downside protection ahead of earnings. The week's sell-off, in other words, was a price move unaccompanied by elevated short positioning or defensive hedging.
The Street leaned constructive going in and had been edging targets higher through the first quarter. Keefe, Bruyette & Woods lifted their target to $186 in early April while maintaining an Outperform. JPMorgan has been a consistent bull, raising its Overweight target twice in the past five months, most recently to $160. With PLMR closing at $111.73 before the print, the mean target of $164 implied roughly 47% upside — a gap that the market was clearly treating with scepticism. On valuation, the trailing P/E compressed to 11x over the past week, down more than a point. Price-to-book fell to 2.3x. Those multiples look modest for a specialty insurer posting beat-and-raise numbers, and the EPS momentum scores remain firm: 69th percentile on 30-day momentum, 88th on 90-day momentum. The bear case — principally the earthquake GWP slowdown and elevated ceded premiums in crop — has weighed on sentiment, but the Q1 beat challenges at least the near-term loss-ratio concern.
CEO Mac Armstrong has been a consistent seller this year, offloading shares across multiple tranches in March and April at prices ranging from $118 to $132. The April activity — nearly $460,000 in gross proceeds across several transactions — is not unusual in isolation for a founder with a sizeable stake, and the award of 6,250 shares on April 15 provides some offset. Net insider flow over 90 days registers a modest net buy of 19,495 shares. The institutional base is well-distributed: BlackRock holds 16.6%, Vanguard 10.2%, and Janus Henderson added a meaningful 568,000 shares in the most recent quarter — a notable build from a large, active manager.
Among peers, the sector sell-off was broad but shallower. SKWD fell 3.6% on the week and SAFT dropped 3.7%. AFG and EG were essentially flat. PLMR's 12% decline stands out relative to the group, pointing to idiosyncratic selling pressure rather than a sector-wide rotation.
The key watch now is how the buyback announcement and the Q1 beat translate into price discovery when the market reopens. The gap between a $111 stock and a $164 mean target, combined with $200 million of authorised repurchase capacity and a clean earnings beat, defines the near-term setup.
See the live data behind this article on ORTEX.
Open PLMR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
